Cargando…
Alteration of protein expression and spliceosome pathway activity during Barrett’s carcinogenesis
BACKGROUND: Barrett’s esophagus (BE) is a known precursor lesion and the strongest risk factor for esophageal adenocarcinoma (EAC), a common and lethal type of cancer. Prediction of risk, the basis for efficient intervention, is commonly solely based on histologic examination. This approach is chall...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370908/ https://www.ncbi.nlm.nih.gov/pubmed/34227026 http://dx.doi.org/10.1007/s00535-021-01802-2 |
_version_ | 1783739530756489216 |
---|---|
author | Stingl, Christoph Bureo Gonzalez, Angela Güzel, Coşkun Phoa, Kai Yi Nadine Doukas, Michail Breimer, Gerben Eise Meijer, Sybren Lodewijk Bergman, Jacques Johannes Luider, Theo Marten |
author_facet | Stingl, Christoph Bureo Gonzalez, Angela Güzel, Coşkun Phoa, Kai Yi Nadine Doukas, Michail Breimer, Gerben Eise Meijer, Sybren Lodewijk Bergman, Jacques Johannes Luider, Theo Marten |
author_sort | Stingl, Christoph |
collection | PubMed |
description | BACKGROUND: Barrett’s esophagus (BE) is a known precursor lesion and the strongest risk factor for esophageal adenocarcinoma (EAC), a common and lethal type of cancer. Prediction of risk, the basis for efficient intervention, is commonly solely based on histologic examination. This approach is challenged by problems such as inter-observer variability in the face of the high heterogeneity of dysplastic tissue. Molecular markers might offer an additional way to understand the carcinogenesis and improve the diagnosis—and eventually treatment. In this study, we probed significant proteomic changes during dysplastic progression from BE into EAC. METHODS: During endoscopic mucosa resection, epithelial and stromal tissue samples were collected by laser capture microdissection from 10 patients with normal BE and 13 patients with high-grade dysplastic/EAC. Samples were analyzed by mass spectrometry-based proteomic analysis. Expressed proteins were determined by label-free quantitation, and gene set enrichment was used to find differentially expressed pathways. The results were validated by immunohistochemistry for two selected key proteins (MSH6 and XPO5). RESULTS: Comparing dysplastic/EAC to non-dysplastic BE, we found in equal volumes of epithelial tissue an overall up-regulation in terms of protein abundance and diversity, and determined a set of 226 differentially expressed proteins. Significantly higher expressions of MSH6 and XPO5 were validated orthogonally and confirmed by immunohistochemistry. CONCLUSIONS: Our results demonstrate that disease-related proteomic alterations can be determined by analyzing minute amounts of cell-type-specific collected tissue. Further analysis indicated that alterations of certain pathways associated with carcinogenesis, such as micro-RNA trafficking, DNA damage repair, and spliceosome activity, exist in dysplastic/EAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00535-021-01802-2. |
format | Online Article Text |
id | pubmed-8370908 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Singapore |
record_format | MEDLINE/PubMed |
spelling | pubmed-83709082021-08-31 Alteration of protein expression and spliceosome pathway activity during Barrett’s carcinogenesis Stingl, Christoph Bureo Gonzalez, Angela Güzel, Coşkun Phoa, Kai Yi Nadine Doukas, Michail Breimer, Gerben Eise Meijer, Sybren Lodewijk Bergman, Jacques Johannes Luider, Theo Marten J Gastroenterol Original Article—Alimentary Tract BACKGROUND: Barrett’s esophagus (BE) is a known precursor lesion and the strongest risk factor for esophageal adenocarcinoma (EAC), a common and lethal type of cancer. Prediction of risk, the basis for efficient intervention, is commonly solely based on histologic examination. This approach is challenged by problems such as inter-observer variability in the face of the high heterogeneity of dysplastic tissue. Molecular markers might offer an additional way to understand the carcinogenesis and improve the diagnosis—and eventually treatment. In this study, we probed significant proteomic changes during dysplastic progression from BE into EAC. METHODS: During endoscopic mucosa resection, epithelial and stromal tissue samples were collected by laser capture microdissection from 10 patients with normal BE and 13 patients with high-grade dysplastic/EAC. Samples were analyzed by mass spectrometry-based proteomic analysis. Expressed proteins were determined by label-free quantitation, and gene set enrichment was used to find differentially expressed pathways. The results were validated by immunohistochemistry for two selected key proteins (MSH6 and XPO5). RESULTS: Comparing dysplastic/EAC to non-dysplastic BE, we found in equal volumes of epithelial tissue an overall up-regulation in terms of protein abundance and diversity, and determined a set of 226 differentially expressed proteins. Significantly higher expressions of MSH6 and XPO5 were validated orthogonally and confirmed by immunohistochemistry. CONCLUSIONS: Our results demonstrate that disease-related proteomic alterations can be determined by analyzing minute amounts of cell-type-specific collected tissue. Further analysis indicated that alterations of certain pathways associated with carcinogenesis, such as micro-RNA trafficking, DNA damage repair, and spliceosome activity, exist in dysplastic/EAC. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s00535-021-01802-2. Springer Singapore 2021-07-05 2021 /pmc/articles/PMC8370908/ /pubmed/34227026 http://dx.doi.org/10.1007/s00535-021-01802-2 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article—Alimentary Tract Stingl, Christoph Bureo Gonzalez, Angela Güzel, Coşkun Phoa, Kai Yi Nadine Doukas, Michail Breimer, Gerben Eise Meijer, Sybren Lodewijk Bergman, Jacques Johannes Luider, Theo Marten Alteration of protein expression and spliceosome pathway activity during Barrett’s carcinogenesis |
title | Alteration of protein expression and spliceosome pathway activity during Barrett’s carcinogenesis |
title_full | Alteration of protein expression and spliceosome pathway activity during Barrett’s carcinogenesis |
title_fullStr | Alteration of protein expression and spliceosome pathway activity during Barrett’s carcinogenesis |
title_full_unstemmed | Alteration of protein expression and spliceosome pathway activity during Barrett’s carcinogenesis |
title_short | Alteration of protein expression and spliceosome pathway activity during Barrett’s carcinogenesis |
title_sort | alteration of protein expression and spliceosome pathway activity during barrett’s carcinogenesis |
topic | Original Article—Alimentary Tract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8370908/ https://www.ncbi.nlm.nih.gov/pubmed/34227026 http://dx.doi.org/10.1007/s00535-021-01802-2 |
work_keys_str_mv | AT stinglchristoph alterationofproteinexpressionandspliceosomepathwayactivityduringbarrettscarcinogenesis AT bureogonzalezangela alterationofproteinexpressionandspliceosomepathwayactivityduringbarrettscarcinogenesis AT guzelcoskun alterationofproteinexpressionandspliceosomepathwayactivityduringbarrettscarcinogenesis AT phoakaiyinadine alterationofproteinexpressionandspliceosomepathwayactivityduringbarrettscarcinogenesis AT doukasmichail alterationofproteinexpressionandspliceosomepathwayactivityduringbarrettscarcinogenesis AT breimergerbeneise alterationofproteinexpressionandspliceosomepathwayactivityduringbarrettscarcinogenesis AT meijersybrenlodewijk alterationofproteinexpressionandspliceosomepathwayactivityduringbarrettscarcinogenesis AT bergmanjacquesjohannes alterationofproteinexpressionandspliceosomepathwayactivityduringbarrettscarcinogenesis AT luidertheomarten alterationofproteinexpressionandspliceosomepathwayactivityduringbarrettscarcinogenesis |